In the nascent industry of medical psychedelics, drug development is the name of the game.
This subset of biotech,poised to become a $100 billion industryaccording toCanaccord Genuity, bases its success on the regulation and approval of scheduled psychoactive substances for mental health and other health indications.
While there are over 100 different clinical trials looking at the therapeutic potential of drugs like ecstasy, LSD, ketamine and magic mushrooms currently underway, our colleagues at Insider identified 18 key trials "that could shape the future of the psychedelics industry by providing crucial information about whether compounds such as psilocybin and MDMA work...